No significant differences in clinicopathological characteristics were observed in our Chinese cohort between BARD1 and BRCA1 mutation carriers, except that carriers of the BRCA1 mutation had a higher incidence of bilateral breast cancer. Here, BARD1 is linked to breast cancer.